Accretion Pharmaceuticals Cash Flow Statement

Financials in millions INR. Fiscal year is April - March.

Millions INR. Fiscal year is Apr - Mar.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Sep '25 Sep 30, 2025	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
Net Income	-	67.94	14.93	1.04	0.79
Depreciation & Amortization	-	7.75	2.24	9.23	8.1
Other Operating Activities	-	25.5	16.9	10.76	10.35
Change in Accounts Receivable	-	-58.57	-70.47	-17.31	12.55
Change in Inventory	-	-61.34	-144.76	-8.31	-19.75
Change in Accounts Payable	-	10.09	66.08	11.12	5.71
Change in Other Net Operating Assets	-	66.14	-	-3.32	3.74
Operating Cash Flow	-	57.5	-115.09	3.21	21.5
Operating Cash Flow Growth	-	-	-	-85.06%	-
Capital Expenditures	-	-16.11	-54.78	-11.78	-2.57
Sale of Property, Plant & Equipment	-	-	-	0.79	-
Investing Cash Flow	-	-16.11	-54.78	-11	-2.57
Long-Term Debt Issued	-	-	134.78	8.58	-
Long-Term Debt Repaid	-	-57.43	-	-	-2.81
Net Debt Issued (Repaid)	-	-57.43	134.78	8.58	-2.81
Issuance of Common Stock	-	30	40	6.59	-
Repurchase of Common Stock	-	-	-	-	-2.87
Other Financing Activities	-	-14.37	-3.99	-10.76	-10.17
Financing Cash Flow	-	-41.8	170.79	4.4	-15.85
Miscellaneous Cash Flow Adjustments	-	0	-	-	-0
Net Cash Flow	-	-0.41	0.92	-3.38	3.08
Free Cash Flow	-	41.39	-169.87	-8.57	18.93
Free Cash Flow Margin	-	7.21%	-127.22%	-2.90%	8.38%
Free Cash Flow Per Share	-	5.16	-22.35	-	-
Cash Interest Paid	-	14.37	3.99	10.76	10.17
Cash Income Tax Paid	-	18.58	-7.89	0.35	0.07
Levered Free Cash Flow	-	-43.95	-111.16	-19.15	-
Unlevered Free Cash Flow	-	-35.28	-109.56	-12.74	-
Change in Working Capital	-	-43.68	-149.15	-17.82	2.26

Source: S&P Capital IQ. Standard template. Financial Sources.